openPR Logo
Press release

World Hemoglobinopathies Market - Opportunities and Forecasts, 2017-2023

09-18-2018 09:37 AM CET | Health & Medicine

Press release from: Allied Market Research

/ PR Agency: Allied Analytics
Hemoglobinopathies Market

Hemoglobinopathies Market

Hemoglobinopathy is a genetic disorder that causes structural abnormalities in hemoglobin molecules, particularly defective globin chains. Hemoglobinopathies are inherited single-gene disorders of which sickle cell disease is the most common kind. There is a high prevalence of Hemoglobinopathies in Africa, Southeast Asia and the Mediterranean basin. If left untreated, critical cases of hemoglobinopathies lead to anemia, organ dysfunction or death. Gel electrophoresis and complete blood count are used as diagnostic tests to determine the presence of hemoglobinopathies. The disease does not have a permanent cure; this has resulted in a growing demand for new product innovations in the pharmaceutical sector. Additionally, the high prevalence of the disease and the national control program are driving the need for drug therapy in developing economies. Alnylam Pharmaceuticals, Gamilda Cell, Sangamo Biosciences, Cancer Therapeutics CRC Pty Ltd and Biogen Idec are some of the key players in this market. These companies have invested huge sums of money in research and development of hemoglobinopathies to develop a permanent cure for this disease. NiCord, ZFP and ALN-TMP are some of the current products available in the market. Companies have adopted the strategy of collaboration and licensing to supplement their research activities.

Access Full Summary: http://bit.ly/2QBAUHg

Global hemoglobinopathies market is segmented on the basis therapeutics and geography. The therapeutic segment includes various drugs such as NiCord, ZFP Transcription Factors, ALN-TMP, Drug Targeting PRMT5 and Drug Targeting Protein Arginine Methyltransferase 5. ALN-TMP is a subcutaneous RNAi therapeutic that targets Tmprss6 and is used in the treatment of β-thalassemia. NiCord®, based on the novel NAM technology, is a potential solution for a number of diseases such as thalassemia, sickle cell disease, hematological malignancies, severe rare genetic metabolic diseases and autoimmune diseases. Geographically, the global hemoglobinopathies market is segmented into North America, Europe, Asia-Pacific and LAMEA. Africa is the leading market for these drugs due to the high prevalence of hemoglobinopathies in the region.

Get Sample Report At: http://bit.ly/2QEgMUX

KEY BENEFITS

The report provides an overview of the global hemoglobinopathies market, which includes drivers, restraints and opportunities to help professionals better understand market behavior
Detailed information regarding R&D activities, pipeline research, partnerships, licensing and collaborations in the global hemoglobinopathies market would be informative for professionals in the corporate sector
Pin-point analysis of geographic segments would help stakeholders identify opportunities for growth within the global hemoglobinopathies market
Porter’s Five Forces analysis examines the competitive structure of the global hemoglobinopathies market and would assist market strategists in their decision making process
KEY MARKET SEGMENTS

The global hemoglobinopathies market is segmented into two major categories: pipeline therapeutics and geography.

MARKET BY PIPELINE THERAPEUTICS

NiCord
ZFP Transcription Factors
ALN-TMP
Drug Targeting PRMT5
Drug Targeting Protein Arginine Methyltransferase 5
MARKET BY GEOGRAPHY

North America
Europe
Asia-Pacific
LAMEA

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Shriram Dighe
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release World Hemoglobinopathies Market - Opportunities and Forecasts, 2017-2023 here

News-ID: 1244400 • Views: 1167

More Releases from Allied Market Research

Arthroscopy Devices Market Key Drivers, Challenges, Growth, Industry Analysis, F …
global market was valued at $3,453 million in 2015 and is projected to reach $5,334 million by 2022, growing at a CAGR of 6.2% from 2016 to 2022. The arthroscopic implants segment held nearly two-fifths of the total market in 2015. Request a Sample Copy of the Research Report: @ https://www.alliedmarketresearch.com/request-sample/426 "Arthroscopy Devices Market research report delivers a comprehensive study on production capacity, consumption, import and export for all major regions across
Dialysis Market Future Growth, Size, Share, Industry Analysis, Scope, Key Player …
The report provides comprehensive analyses of the top winning strategies, industry dynamics, market size & estimations, key market segments, and competitive landscape. According to the report, the global dialysis market is expected to reach $118.51 billion by 2023 from $91 billion in 2017, registering a CAGR of 4.4% from 2018 to 2023. Request a Sample Copy of the Research Report: @ https://www.alliedmarketresearch.com/request-sample/374 Increase in government funding for dialysis, rise in incidence of
IV Quality Control Products Market is projected to reach $1,052 million by 2022, …
The global IVD quality control products market was valued at $823 million in 2015, and is expected to reach $1,052 million by 2022, registering a CAGR of 3.5% from 2016 to 2022. The quality controls products segment dominated the market with fourth-fifths share in 2015. Immunochemistry and clinical chemistry application segments together captured around half of the market share in 2015. Request a Sample Copy of the Research Report: @ https://www.alliedmarketresearch.com/request-sample/1792 "In
Electric Passenger Car Traction Motor Market Growth 2027 – Key drivers, Busine …
Traction motor produces resistance between two surfaces with or without using electricity. An electric passenger car traction motor is a vital component which is used for extracting electricity from the battery pack. Traction motor is installed in electric passenger vehicles to provide rotation torque for the movement of the car. Furthermore, stringent emission discharge norms and regulations drives the demand for electric passenger car. Moreover, quick expansion of EV charging

All 5 Releases


More Releases for Hemoglobinopathies

Hemoglobinopathies Market 2020E Analysis, Key Players and Forecast 2026E
Facts & Factors Market Research, a leading market research and consulting firm added the latest industry outlook report on "Hemoglobinopathies Market 2020 By Excellent Opportunities, Industry Growth, Size, And Statistics Forecasts Up To 2026" consisting of 190+ pages during the forecast period 2020 to 2026 and the Hemoglobinopathies Market report offers comprehensive research updates and information related to market growth, demand, and opportunities in the Hemoglobinopathies Market. The Hemoglobinopathies market report
Hemoglobinopathies Market to Develop Rapidly by 2024
The U.S. National Library of Medicine defines hemoglobinopathy as a group of disorders passed down from one generation to another that are characterized by an abnormal structure or production of the hemoglobin molecule. Hemoglobinopathy disorders include sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and various forms of thalassaemia. The growing prevalence of hemoglobinopathy disorders, particularly sickle cell anemia, has boosted the growth of the global Hemoglobinopathies Market. Though the
Hemoglobinopathies Market Key Growth Factors and Forecast Upto 2024
The U.S. National Library of Medicine defines hemoglobinopathy as a group of disorders passed down from one generation to another that are characterized by an abnormal structure or production of the hemoglobin molecule. Hemoglobinopathy disorders include sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and various forms of thalassaemia. The growing prevalence of hemoglobinopathy disorders, particularly sickle cell anemia, has boosted the growth of the global hemoglobinopathies market. Report Overview
Hemoglobinopathies Market – Industry Analysis, Share, Research Report 2023
Hemoglobinopathies Market size is driven by high occurrence in underdeveloped nations such as Arab nations, Sub-Saharan region and South East Asia. Hemoglobinopathies Market size was valued at over USD 4 billion in 2015. Other key reasons for disease prevalence include lack of patient awareness, unmet needs for treatment, and absence of permanent cure. Lack of awareness for treatment and diagnosis of such rare diseases generates huge untouched opportunities in the industry.
Hemoglobinopathies Market - Global Industry Analysis 2016 - 2024
Global Hemoglobinopathies Market: Overview Among various hemoglobinopathy disorders, sickle cell anemia is the most common inherited blood disease. According to the World Health Organization (WHO), around 5% of the world’s population carries trait genes for hemoglobinopathy disorders such as thalassaemia and sickle cell
Hemoglobinopathies Market Driven by Extensive Research and Development Activitie …
Global Hemoglobinopathies Market: Description The U.S. National Library of Medicine defines hemoglobinopathy as a group of disorders passed down from one generation to another that are characterized by an abnormal structure or production of the hemoglobin molecule. Hemoglobinopathy disorders include sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and various forms of thalassaemia. The growing prevalence of hemoglobinopathy disorders, particularly sickle cell anemia, has boosted the growth of the global